Unicycive Therapeutics In... (UNCY)

AI Score

Unlock

0.65

0.01 (1.56%)

At close: Apr 25, 2025, 9:43 AM

Unicycive Therapeutics Cash Flow Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021	Q4 2020	Q3 2020	Q2 2020	Q1 2020	Q4 2019	Q3 2019	Q2 2019	Q1 2019
Period Ending	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net Income	-42.65M	-28.93M	-29.16M	-36.93M	-30.54M	-28.07M	-29.3M	-29.1M	-18.06M	-15.48M	-15.13M	-12.59M	-10.02M	-8.14M	-3.65M	-2.88M	-2.26M	-2.09M	-1.95M	-2.06M	-2.17M	-1.46M	-899K	-449.5K
Depreciation & Amortization	428K	376K	332K	523K	284K	244K	205K	167K	161K	120K	80K	40K	1K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Stock-Based Compensation	2.35M	2.32M	2.64M	2.15M	1.77M	1.41M	751K	901K	1.05M	1.08M	1.05M	1.05M	966K	806K	637K	403K	232K	185K	115K	55K	24K	n/a	n/a	n/a
Other Working Capital	-1.59M	-1.63M	688K	-582K	-1.46M	-2.53M	-1.61M	-123K	-89K	716K	-740K	-1.02M	-1.35M	-1.76M	-124K	-172K	-98K	-125K	72K	23.5K	-3K	12K	-103K	-51.5K
Other Non-Cash Items	12M	1.33M	1.69M	12.29M	10.59M	8.72M	8.47M	9.15M	-913K	-1.02M	3.39M	3.42M	3.39M	3.72M	1.16M	873K	739K	744K	883K	916.5K	968K	724K	377K	188.5K
Deferred Income Tax	n/a	-287K	-287K	-287K	-287K	n/a	1.65M	1.24M	1.24M	1.24M	-406K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Change in Working Capital	-427K	-1.01M	3.42M	1.71M	-93K	-2.23M	-841K	1.02M	1.18M	3.4M	435K	328K	-105K	-1.28M	-284K	-451K	-166K	-213K	184K	151.5K	-3K	12K	-103K	-51.5K
Operating Cash Flow	-28.57M	-26.47M	-21.64M	-20.82M	-18.28M	-19.93M	-19.07M	-16.61M	-15.65M	-10.97M	-10.88M	-8.05M	-5.77M	-4.9M	-2.13M	-2.06M	-1.46M	-1.37M	-766K	-936.5K	-1.18M	-727K	-625K	-312.5K
Capital Expenditures	-72K	-50K	-26K	-18K	-12K	-14K	-14K	-2K	-4K	-31K	-31K	-31K	-29K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cash Acquisitions	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Purchase of Investments	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Sales Maturities Of Investments	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Investing Acitivies	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Investing Cash Flow	-72K	-50K	-26K	-18K	-12K	-14K	-14K	-2K	-4K	-31K	-31K	-31K	-29K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Debt Repayment	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	174K	875K	1.38M	2.24M	2.11M	1.42M	919K	59K	10K	n/a	n/a	n/a	n/a
Common Stock Repurchased	n/a	-11.66B	11.75B	-1.33B	-1.33B	10.32B	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Dividend Paid	-1.3M	-2.17M	-2.17M	-1.07M	-1.06M	-192K	-192K	-192K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Financial Acitivies	-4K	-574K	-468K	-752K	-2.65M	-2.93M	-2.88M	-2.88M	-482K	18.72M	40.2M	40.1M	40.22M	21.48M	-101K	94K	25K	513K	707K	915.5K	1.17M	703K	601K	300.5K
Financial Cash Flow	45.09M	44.52M	44.62M	45.44M	27.54M	27.27M	27.33M	27.33M	-471K	n/a	21.48M	21.55M	22.38M	22.85M	2.13M	2.2M	1.44M	1.43M	766K	925.5K	1.17M	703K	601K	300.5K
Net Cash Flow	16.44M	18M	22.96M	24.6M	9.25M	7.33M	8.24M	10.71M	-16.12M	-11M	10.57M	13.47M	16.58M	17.95M	n/a	145K	-15K	62K	n/a	-11K	-10K	-24K	-24K	-12K
Free Cash Flow	-28.65M	-26.52M	-21.66M	-20.84M	-18.3M	-19.94M	-19.08M	-16.62M	-15.65M	-11M	-10.91M	-8.08M	-5.8M	-4.9M	-2.13M	-2.06M	-1.46M	-1.37M	-766K	-936.5K	-1.18M	-727K	-625K	-312.5K